Short answer
Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on October 14, 2026 reporting Item 3.02 (Unregistered Sales of Equity Securities), Item 8.01 (Other Events). Gilead agreed to purchase 1,765,486 Vir shares at $14.16, providing approximately $25 million in financing.
Vir Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.02 · Unregistered Sales of Equity Securities
- Gilead agreed to purchase 1,765,486 Vir shares at $14.16, providing approximately $25 million in financing
- Sale structured as an unregistered private placement under Securities Act Section 4(a)(2), avoiding public offering registration
- One-year standstill, voting and lockup provisions limiting Gilead’s shareholder actions
- Gilead gains conditional resale registration rights one year after anticipated closing
- Equity investment accompanies global collaboration targeting three novel solid-tumor T-cell engager candidates
Item 8.01 · Other Events
- Vir entered an agreement and securities purchase agreement with Gilead, signaling a new strategic financing or collaboration arrangement
- Exhibit 99.1 contains the substantive transaction terms, including Vir’s obligations and potential economics
- Collaboration targets three novel PRO-XTEN dual-masked TCE candidates for selected solid tumor antigens
- Value depends on successful discovery, preclinical development and potential commercialization, with substantial execution and regulatory risk
- Investors should review Exhibit 99.1 for upfront consideration, milestones, royalties and financing impact
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vir Biotechnology, Inc. 8-K filings
Get the next VIR 8-K as it lands
Follow VIR for push alerts, or ask the research agent what this filing means.